Engineered Modular Recombinant Transporters: Application of New Platform for Targeted Radiotherapeutic Agents to α-Particle Emitting 211At

The results of this study have demonstrated the initial proof of principle for the MRT approach for designing targeted α-particle emitting radiotherapeutic agents. The high cytotoxicity of SAGMB-MRT for cancer cells overexpressing EGFR suggests that this 211At-labeled conjugate has promise for the treatment of malignancies, such as glioma, which overexpress this receptor.